• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

When the Data Doesn't Matter

It seems we've lost all semblance of sanity. Let's look at two companies to see the craziness of the market we're in.
By TIMOTHY COLLINS
Dec 09, 2020 | 04:46 PM EST
Stocks quotes in this article: QS, GLSI

Take rationality and throw it out the freaking door. Take the idea of shorting anything other than big names and indexes and toss it out the window.
 
We've lost the last semblance of sanity.
 
If you haven't already realized it, traditional metrics don't matter. And shorting individual momentum stocks in this market is scarier than heck. The problem isn't just finding a top, it's knowing there may not be a top you can live through.
 
Take Quantumscape ( QS)  as an example. The company looked aggressive when it hit $30, but the excitement and potential -- plus the strong backers -- made it feasible. Then, a quick run to $50 with production since half a decade away made it a head-scratcher. All it took was PR on a successful tiny test of the tech to move shares from $50 to a high of $87.50.
 
With the stock trading around $77, the market is now $34.5 billion. And that assumes none of the warrants see the light of day as shares. Management of the two companies projected the 2028 Enterprise Value in the range of $32 billion to $58 billion with $45 billion as the midpoint. With the current Enterprise Value at $33.3 billion in 2020, one does have to wonder about the market.
 
We're not talking about management projections for 2022 or 2024 and we're seeing some pull forward or valuation adjustment because of the recent small trial test success. We're seeing valuation enter the range the management of the very company deemed appropriate for 2028!
 
Still, I can see some misguided logic in this. QS could become the next generation battery with a huge advantage over existing products. And it could stretch outside vehicle battery to other storage or other applications.
 
But turn the page to Greenwich Lifesciences ( GLSI) . The company entered the day with a market of $62 million. Around the highs of the day that number increased to $1.9 billion. That's billion with a "B." Let's call it a 3000% gain. The company grabbed attention with these headlines:

"Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer."

 
This is definitely eye-popping. I would note it is not phase three, so there's still work to be done. No doubt the $62 million market cap no longer fits the risk-reward, but $2 billion? I'm sure some pros better suited to biotech will chime in, but $2 billion feels more like strong phase III results or even post-Food and Drug Administration approval. I've seen some doubts cast on whether the trial was actually a success or not.
 
But combine a sexy headline with a stock housing a float under 2 million shares, and you get electricity. Add in the bonus of an initial price tag in the single digits, and you get the same thing we've seen all year: Greater Fool Theory. This market is creating more millionaires and bagholders on the same day in a single security than any time I can remember. In short, chasers are getting ruined, but those who can find the names (and encourage others to follow) are making a killing.
 
It also makes shorting next to impossible, because there is no rationality to the buying. On the GLSI news we're seeing unrelated cancer stocks pop, because they are simply low dollar with a low float. You can call it trading (I do) but you can also call it gambling.
 
The current thesis:
 
Find a "cancer" stock in the single digits with a low float.
 
Q: What does it do?
A: Who cares.
 
Q: How's their tech?
A: Doesn't matter.
 
Q: Management?
A: They're breathing and have a heartbeat.
 
Q: History of the science?
A: It's in the past, so who cares.
 
Q: Do they have a trial?
A: Aren't we all on trial?
 
I'm in!
 
We're accustomed to some sense of gambling with trading and stocks, especially if you trade momentum. But when we see moves like this, a creeping worry about the overall market health enters the back of your mind. Yes, we're seeing wealth created for those who get in early and don't overstay their welcome. I worry, too, that we're ruining a multitude of new traders to the market that were drawn in by the huge gains they see being discussed.
 
The short of this: Be careful out there. More signs of froth are hitting every day. I suspect we'll get another day like today with these big clips of 5% to 10% on individual names in the next few days. That's when I'll look to buy. For now, I'm around 2/3rds in cash with a few select positions. Ironically, that's all you need these days to still perform well. I think it's the right approach for the next week. That's how I'm playing it.
 
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Tim Collins was long QS put butterfly.

TAGS: Investing | Options | Stocks | Biotechnology | Electric Vehicles

More from Stocks

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

The Price Damage for Roku Is Not Over Yet

Bruce Kamich
Mar 5, 2021 1:25 PM EST

It looks like further declines are possible. Avoid the long side.

Roll the Dice on This Bounce

Timothy Collins
Mar 5, 2021 1:03 PM EST

This has given investors an opportunity to load up on small speculative names I love over the next 12 to 18 months.

Walgreens Boots Alliance Is Likely to Weaken Further

Bruce Kamich
Mar 5, 2021 12:44 PM EST

Let's check out the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login